Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10557854-B2

Patent

Publication Date

2020-02-11

Expiration Date


Abstract

The present disclosure relates to compounds that are useful as near-infrared fluorescence probes, wherein the compounds include i) a ligand that binds to the active site of carbonic anhydrase, ii) a dye molecule, and iii) a linker molecule that comprises an amino acid, amide, ureido, or polyethylene glycol derivative thereof. The disclosure further describes methods and compositions for making and using the compounds, methods incorporating the compounds, and kits incorporating the compounds.

Core Innovation

The disclosure provides CA IX-targeted near-infrared dye conjugates in which a CA IX-targeted molecule is linked with an extended hydrophobic residue, a hydrophobic spacer, an amino acid spacer, and a NIR dye. The compounds are defined by a structural formula B-W-X-Y-Z, and the scaffold is further refined by linker design and selected NIR dye structures. The disclosure also provides CA IX-targeted ligand scaffolds and derivatives culminating in a CA-IX dye conjugate compound.

The described chemistry includes substituted sulfonyl- or thio-containing propanoic acid intermediates, including 3-((2,3,5,6-tetrafluoro-4-sulfamoylphenyl)thio/sulfonyl)propanoic acids, followed by amination to install cyclooctylamino ligands, including meta- and ortho-substituted ligands. Linker installation is carried out by couplings with protected tyrosine/PEG linkers and subsequent deprotection, yielding linkers suitable for final conjugation. The final step forms dye/conjugate compounds with a thioindoline-type NIR dye (S0456) under basic conditions.

The disclosure focuses on fluorescence-based optical imaging and optical detection of CA IX-expressing cells in biological samples, including contexts where improved performance is desired for image-guided surgery and disease diagnosis. The compounds target CA IX, including hypoxia/hypoxic tumor targeting, with emphasis on optical signal properties and contrast in biological tissue, reducing background autofluorescence and improving tumor-to-background ratio. The text reports whole-body IVIS imaging within 2–24 h, strong tumor accumulation, retained fluorescence over 24 h, CA IX-mediated selective uptake, and low uptake in other healthy tissues.

Claims Coverage

The partial claim set includes two independent claims. The inventive features center on CA IX-targeted molecule conjugates to a NIR dye with explicit separation into extended hydrophobic residue, hydrophobic spacer, and amino acid spacer, plus a second structural formula that defines variable substituent choices to tune spectral properties, linker composition, hydrophobicity, and binding affinity.

CA IX-targeted compound scaffold with extended hydrophobic residue, hydrophobic spacer, amino acid spacer, and NIR dye

A compound having the formula B-W-X-Y-Z wherein B is a CA IX-targeted molecule, W is an extended hydrophobic residue, X is a hydrophobic spacer, Y is an amino acid spacer, and Z is a NIR dye.

Variable-structure compound defined by R19-R30 substituent options

A compound having a structural formula, or a pharmaceutically acceptable salt thereof, or isotopes thereof, with substituent definitions including R19 as hydrogen or SO3H; R20 as hydrogen or specified substituted or ionic groups; R21 and R22 as allowed carbon features; R23 as nitrogen, oxygen, sulfur, or no atom; and R24-R30 as optional aromatic substitution, linker, hydrophobic moiety, and hydrophobic linker choices.

Overall, the claim coverage centers on CA IX-targeted near-infrared dye conjugates that include an extended hydrophobic residue, a hydrophobic spacer, and an amino acid spacer, together with a detailed structural formula containing enumerated substituent choices for spectral and molecular tuning.

Stated Advantages

Higher tumor-to-background ratio.

Reduced background autofluorescence.

Improved surgical margins or clean margins.

Improved efficacy for detection of small, deep tumors.

Lower dye dose.

Ability to detect small, deep tumors several mm below skin.

Whole-body imaging within 2-24 h.

Strong tumor accumulation.

High tumor-to-background and tumor-to-skin performance.

Retained fluorescence over 24 h.

CA IX-mediated selective uptake attributed to hypoxia-induced CA IX induction.

Low uptake in other healthy tissues.

Documented Applications

Fluorescence-based optical imaging of CA IX-expressing biological tissue by contacting the tissue with a composition containing the compound, illuminating with excitation light absorbable by the compound, and detecting the emitted optical signal.

Optical detection of CA IX-expressing cells in biological samples.

Image-guided surgery, including detection to support improved surgical margins or clean margins.

Disease diagnosis, including diagnosis based on CA IX-targeted NIR dye conjugate imaging.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.